FULC FY 2021 Earnings — Fulcrum Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

FULCFulcrum Therapeutics, Inc.

$436M

FY 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$19M+117.2% YoY

Gross Profit

-$51M-263.7% margin

Operating Income

-$81M-423.0% margin

Net Income

-$81M-421.9% margin

EPS (Diluted)

$-2.22

Cash Flow

Operating Cash Flow

-$78M

Free Cash Flow

-$80M

Stock-Based Comp.

$11M

Balance Sheet

Total Assets

$235M

Total Liabilities

$23M

Stockholders' Equity

$212M

Cash & Equivalents

$35M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$19M	$9M	+117.2%
Gross Profit	-$51M	-$50M	-0.6%
Operating Income	-$81M	-$72M	-13.2%
Net Income	-$81M	-$71M	-14.2%